Finanzen von Apellis Pharmaceuticals Inc (APLS)APLSApellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc (APLS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is SYFOVRE, accounting for 56.2% of total sales, equivalent to $150.72M. Other significant revenue streams include Licensing and other revenue and EMPAVELI. Understanding this composition is critical for investors evaluating how APLS navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Apellis Pharmaceuticals Inc maintains a gross margin of 84.89%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.86%, while the net margin is 6.95%. These profitability ratios, combined with a Return on Equity (ROE) of 46.02%, provide a clear picture of how effectively APLS converts its operational activities into shareholder value.

In the context of the broader market, APLS competes directly with industry leaders such as XENE and PTCT. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, APLS's gross margin of 84.89% stands against XENE's N/A and PTCT's 91.19%. Such benchmarking helps identify whether Apellis Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.